Albatroz Therapeutics
Singapore, Singapore· Est.
Innovative antibodies targeting Calnexin to protect extracellular matrix and treat cancer, arthritis, and IBD.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Innovative antibodies targeting Calnexin to protect extracellular matrix and treat cancer, arthritis, and IBD.
OncologyRheumatologyGastroenterology
Technology Platform
Monoclonal antibodies that bind and inhibit Calnexin, preventing extracellular matrix degradation and thereby blocking tumor invasion, cartilage loss, and intestinal inflammation.
Opportunities
High unmet need for non‑toxic disease‑modifying therapies across oncology, arthritis, and IBD; potential for strategic partnerships or out‑licensing.
Risk Factors
Target validation in humans, regulatory pathway uncertainty, and competition from other ECM‑targeting modalities.
Competitive Landscape
Few companies focus on Calnexin; Albatroz differentiates through a novel, highly specific target and a unified ECM‑preservation approach across multiple disease areas.